Alzheimer and gene therapy in two minutes

A new path for Alzheimer's Disease

Our therapy

Our roadmap has been validated by the AEMPS

Pipeline

A new path for Alzheimer's Disease

About us

Gene Therapy

Innovative and disruptive multifactorial gene therapy for treating Alzheimer’s disease

Road map

Road map validated by the Spanish Agency of Medicines and Healthcare Products (AEMPS)

Scientific team

A scientific team made up of researchers with over 30 years’ experience in neuroscience

Tetraneuron

First Spanish Biotech Start-up at the Johnson & Johnson European Innovation Centre

Tetraneuron was founded as a spin-off from the Cajal Institute belonging to the Spanish Scientific Research Council (CSIC).
We are developing an innovative and disruptive multifactorial gene therapy to treat Alzheimer’s disease, as well as a biomarker for early detection of this terrible disease.

About us

Tetraneuron Corporate video

Our History

2012

Tetraneuron was founded

2013

Identification of therapeutic target. E2F4

2014

Beginning of the proof of concept

2015

Validation of therapeutic target: E2F4DN

2016

Identification of the Leading Compound

2017

Validation of the Leading Compound

2018

Validation of the Leading Compound

2019

Analysis of biological processes modulated by E2F4DN

2020

Method validation of AAV9-E2F4DN

2021

Beginning of preclinical regulatory Phase

Lines of research

Tetraneuron is actively working on two lines of research, both derived from the phosphorylation of E2F4 during the earliest stages of Alzheimer’s disease.

Find out more

Multifactorial gene therapy

Gene therapy based on E2F4DN. A promising approach for Alzheimer’s disease.

More info

Biomarker for the early diagnosis

A method to determine the risk of developing Alzheimer’s disease at an early stage.

More info

Scientific articles

Pathological aspects of neuronal hyperploidization in Alzheimer’s disease evidenced by computer simulation (2020)

Leer artículo

Primary neurons can enter M-phase (2019)

Leer artículo

Cell cycle reentry triggers hyperploidization and synaptic dysfunction followed by delayed cell death in differentiated cortical neurons (2018)

Leer artículo

See all

Our team

The scientific team consists of personnel with more than 30 years of experience in neuroscience and executives from biopharmaceutical companies as associates.